Apixaban to Prevent Recurrence After Cryptogenic Stroke in P

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy

This clinical trial compares the effectiveness of anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke an

Related Keywords

United States , New York , Boston , Massachusetts , Canada , Canadian , American , Bristol Myers Squibb , Daichi Sankyo , Hooman Kamel , Group Information , Medtronic , National Institutes Of Health , Drug Administration , Strokenet National Coordinating Center , Atria Academy For Science , Pfizer , Clinical Laboratory Improvement Amendments , National Institutes Of Health Strokenet , Health Canada , University Of Cincinnati , Alliance For Eliquis , Strokenet National Data Management Center , Astrazeneca , Canadian Stroke Consortium , Novo Nordisk , Burke Porter Group , Strokenet Regional Coordinating Center , University Of South Carolina , Population Health Research Institute , American Heart Association , National Institute Of Neurological Disorders , Genentech , University Of Washington , Boehringer Ingelheim , Boston Scientific , Spectrum Plastics Group , Kroger Prescription Plans Inc Pharmacy Therapeutics Committee , National Institutes , Health Strokenet , Canadian Stroke , Atrial Cardiopathy , Antithrombotic Drugs , Prevention After Cryptogenic Stroke , Medical University , South Carolina , Population Health Research , Investigational New Drug , Strokenet Central Institutional Review Board , Rankin Scale , American Indian , Alaska Native , Native Hawaiian , Roche Diagnostics , Strokenet Regional Coordinating , Size Calculation , Hispanic White , Trial Termination , African American , Weill Cornell Medicine , Interest Disclosures , Deputy Editor , Burke Porter , National Institute , Neurological Disorders , Basking Biosciences , Kroger Prescription Plans Inc , Therapeutics Committee , Pfizer Alliance , Atria Academy , American Heart , Strokenet Central Pharmacy ,

© 2025 Vimarsana